Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | FADS1 | O60427 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29565502 | 1.00 | KMT2A (0.61) | KMT2AMEN1LMNAFADS1HTT | |
| SCHEMBL20415615 | 0.95 | MEN1 (0.56) | KMT2AMEN1LMNAFADS1HTT | |
| SCHEMBL9541314 | 0.89 | FADS1 (0.69) | KMT2AMEN1LMNAFADS1ADRA2A | |
| SCHEMBL31300377 | 0.89 | FADS1 (0.69) | KMT2AMEN1LMNAFADS1ADRA2A | |
| SCHEMBL3564108 | 0.87 | LMNA (0.55) | KMT2AMEN1LMNAFADS1HTT | |
| SCHEMBL8811675 | 0.87 | LMNA (0.58) | KMT2AMEN1LMNAFADS1HTT | |
| SCHEMBL2115700 | 0.85 | HTT (0.63) | KMT2AMEN1LMNAHTTADRA2A | |
| SCHEMBL31285743 | 0.83 | ALDH1A1 (0.60) | KMT2AMEN1LMNAHTTALDH1A1 | |
| SCHEMBL3564275 | 0.81 | MEN1 (0.66) | KMT2AMEN1LMNAHTTADRA2A | |
| SCHEMBL29789626 | 0.81 | MEN1 (0.66) | KMT2AMEN1LMNAHTTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170209539-A1 | Therapeutic Treatment For Metabolic Syndrome, Type 2 Diabetes, Obesity, Or Prediabetes | VEROSCIENCE LLC (US) | 2017-07-27 | — | — | US | claimed |
| US-9655865-B2 | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes | VEROSCIENCE, LLC (US) | 2017-05-23 | — | — | US | claimed |
| US-20130274246-A1 | Therapeutic Treatment for Metabolic Syndrome, Type 2 Diabetes, Obesity, or Prediabetes | VEROSCIENCE, LLC | 2013-10-17 | — | — | US | claimed |
| EP-2579876-A2 | THERAPEUTIC TREATMENT FOR METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY, OR PREDIABETES | VeroScience LLC (US) | 2013-04-17 | — | — | EP | claimed |
| WO-2011156248-A2 | THERAPEUTIC TREATMENT FOR METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY, OR PREDIABETES | VEROSCIENCE, LLC (US) | 2011-12-15 | — | — | WO | claimed |
| EP-2162003-A1 | THERAPEUTIC TREATMENT FOR METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY, OR PREDIABETES | VeroScience LLC (US) | 2010-03-17 | — | — | EP | claimed |
| WO-2008150480-A1 | THERAPEUTIC TREATMENT FOR METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY, OR PREDIABETES | VEROSCIENCE, LLC (US) | 2008-12-11 | — | — | WO | claimed |
| US-20080293735-A1 | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes | VEROSCIENCE, LLC | 2008-11-27 | — | — | US | claimed |
| US-20050054734-A1 | Therapeutic treatment for the metabolic syndrome, type2 diabetes, obesity, or prediabetes | CINCOTTA ANTHONY H (US) | 2005-03-10 | — | — | US | claimed |
| US-20230106317-A1 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2023-04-06 | — | — | US | disclosed |
| CN-113348172-B | Compound and organic light emitting device including the same | 株式会社LG化学 | 2022-10-11 | — | — | CN | disclosed |
| CN-113924307-A | Polycyclic compound and organic light-emitting element comprising same | 株式会社LG化学 | 2022-01-11 | — | — | CN | disclosed |
| CN-113348172-A | Compound and organic light emitting device including the same | 株式会社LG化学 | 2021-09-03 | — | — | CN | disclosed |
| WO-2021107711-A1 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | 주식회사 엘지화학 | 2021-06-03 | — | — | WO | disclosed |
| WO-2000059489-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC AND RELATED DISORDERS USING ZIPRASIDONE METABOLITES | SEPRACOR INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-0939841-A1 | PREPARATION OF FIBERS CONTAINING INTRINSICALLY CONDUCTIVE POLYMERS | Zipperling Kessler & Co (GmbH & Co) (DE) | 1999-09-08 | — | — | EP | disclosed |
| WO-1999035308-A2 | ANODICALLY FORMED INTRINSICALLY CONDUCTIVE POLYMER-ALUMINUM OXIDE COMPOSITE AS A COATING ON ALUMINUM | ZIPPERLING KESSLER & CO. (GMBH & CO.) (DE) | 1999-07-15 | — | — | WO | disclosed |
| WO-1999025778-A1 | SYNTHESIS AND APPLICATIONS OF INTRINSICALLY CONDUCTIVE POLYMER SALTS OF POLYPHOSPHONIC ACIDS IN ANTI-CORROSION COATINGS | ZIPPERLING KESSLER & CO. (GMBH & CO.) (DE) | 1999-05-27 | — | — | WO | disclosed |
| WO-1999015725-A1 | PREPARATION OF FIBERS CONTAINING INTRINSICALLY CONDUCTIVE POLYMERS | ZIPPERLING KESSLER & CO. (GMBH & CO.) (DE) | 1999-04-01 | — | — | WO | disclosed |
| WO-1999016084-A1 | ELECTRICALLY CONDUCTIVE BLOCK COPOLYMERS CONTAINING AN INTRINSICALLY CONDUCTIVE POLYMER | ZIPPERLING KESSLER & CO. (GMBH & CO.) (DE) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106317-A1 | POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | CCNL2, NR1H3, NR1H2 | KMT2A 1761/4885MEN1 1592/4885LMNA 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.